Skip to Content
Merck
CN

SML3887

Sigma-Aldrich

DS-5272

≥98% (HPLC)

Synonym(s):

DS 5272, [(2S,4R)-1-[[(5R,6S)-5-(4-Chloro-3-fluorophenyl)-6-(6-chloro-3-pyridinyl)-5,6-dihydro-6-methyl-3-(1-methylethyl)imidazo[2,1-b]thiazol-2-yl]carbonyl]-4-fluoro-2-pyrrolidinyl][(6R)-6-ethyl-4,7-diazaspiro[2.5]oct-7-yl]methanone

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

Empirical Formula (Hill Notation):
C34H38Cl2F2N6O2S
CAS Number:
Molecular Weight:
703.67
UNSPSC Code:
12352200
NACRES:
NA.77
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

Orally active and potent inhibitor of p53-MDM2 interaction.
DS-5272 is an orally active and potent inhibitor of p53-MDM2 interaction that exhibits efficacy against number of tumors including acute myeloid leukemia (AML). DS-5272 induces an immune-inflammatory response in MLL-AF9 cells.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Discovery of DS-5272 as a promising candidate: A potent and orally active p53-MDM2 interaction inhibitor
Bioorganic & Medicinal Chemistry, 23(10), 2360-2367 (2015)
Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated
Biochemical Pharmacology, 71(1-2), 13-20 (2005)
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model
Haematologica, 105(5), 1274-1284 (2020)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service